Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma

Inclusion Criteria: * Patients must satisfy all the following criteria for entry into the protocol: Primary CBCL including (according to WHO/EORTC classification 2005) : * Primary cutaneous marginal zone B-cell lymphoma * Primary cutaneous follicle center B-cell lymphoma * Primary cutaneous diffuse large B-cell other than leg type * Histologically consistent with primary CBCL. * Relapse or active disease after radiotherapy or other adequate therapy if radiotherapy was contra-indicated (chemotherapy, surgical excision, interferonα, rituximab). * Performance status of 0, 1 on the Eastern Cooperative Oncology Group (ECOG) scale (See Appendix E). * Minimum Life Expectancy \> 3 months. * Adequate blood count: hemoglobin \>= 10.0 g/dL; White Blood Count (WBC) \>= 3.0 x 109/L; and platelet count \>= 75 x 109/L. * Adequate hepatic function: bilirubin =\< 1.5 times the upper limit of normal and serum transaminase (SGOT and SGPT)=\< 2.5 times the upper limit of normal. * Adequate renal function: creatinine =\< 1.5 times the upper limit of normal. * Written informed consent from patient. Exclusion Criteria: Patients will be excluded from the study for any of the following reasons: * Primary cutaneous diffuse large B-cell lymphoma, leg type. * Primary cutaneous intravascular large B-cell lymphoma. * Extracutaneous involvement (sign of B-cell lymphoma on thoraco-abdominal CT scan and/or PET scan and/or on bone marrow biopsy). * No histologic documentation of CBCL. * History of known Human Immuno-deficiency Virus, Human Hepatitis B or C positive serology or other active systemic infections. * Serious uncontrolled, concomitant medical disorders. * Concomitant therapy for CBCL: surgical resection, radiotherapy, corticosteroid, chemotherapy, rituximab…(not limited listing) * Major surgery in previous 4 weeks preceding the 1st injection. * Pregnancy at study entry or who become pregnant during the study or women who are breast feeding. * Males and females of reproductive potential who refuse to use adequate protection against pregnancy (intra-uterine device, hormonal contraception or diaphragm/condom and spermicide) during the conduct of the study and for three months after the last injection. * Participation in another experimental protocol during the study period and within 4 weeks prior to the first injection. * Patient previously included in this study. * Non compliance with the study.